Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.59 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.59 |
| ▸ | SYK | P43405 | 11/20 | 0.58 |
| ▸ | CD63 | P08962 | 3/20 | 0.58 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.52 |
| ▸ | ROS1 | P08922 | 1/20 | 0.52 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.52 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.52 |
| ▸ | BTK | Q06187 | 1/20 | 0.52 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.52 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.52 |
| ▸ | ADK | P55263 | 1/20 | 0.48 |
| ▸ | XDH | P47989 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17536351 | 0.90 | PIK3CA (0.56) | PIK3CAPIK3R1SYKCD63AURKA | |
| SCHEMBL2482275 | 0.81 | AURKA (0.79) | SYKCD63AURKAJAK2NTRK1 | |
| SCHEMBL5478336 | 0.80 | RAB9A (0.59) | PIK3CAPIK3R1SYKCD63AURKA | |
| SCHEMBL5408059 | 0.77 | ADORA1 (0.68) | AURKAJAK2NTRK1FLT3KDM4E | |
| SCHEMBL30806177 | 0.77 | TLR9 (0.45) | PIK3CAPIK3R1SYKCD63JAK2 | |
| SCHEMBL23911850 | 0.76 | AURKA (0.81) | SYKCD63AURKAJAK2NTRK1 | |
| SCHEMBL24864097 | 0.74 | SYK (0.79) | PIK3CAPIK3R1SYKCD63AURKA | |
| SCHEMBL2481188 | 0.74 | SYK (0.73) | SYKCD63AURKAJAK2NTRK1 | |
| SCHEMBL15603021 | 0.74 | PIK3CA (1.00) | PIK3CAPIK3R1 | |
| SCHEMBL18189906 | 0.74 | PIK3R1 (0.55) | PIK3CAPIK3R1AURKAKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158023-A1 | CRYSTALLINE SUCCINATE SALT OF 6-(6-AMINOPYRAZIN-2-YL)-N-(4-(4-(OXETAN-3-YL)PIPERAZIN-1-YL)PHENYL)IMIDAZO[1,2-a]PYRAZIN-8-AMINE | GILEAD SCIENCES, INC. | 2023-05-25 | — | — | US | disclosed |
| US-11517570-B2 | Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine | Kronos Bio, Inc. (US) | 2022-12-06 | — | — | US | disclosed |
| US-20210060011-A1 | CRYSTALLINE MONOMESYLATE SALT OF 6-(6-AMINOPYRAZIN-2-YL)-N-(4-(4-(OXETAN-3-YL)PIPERAZIN-1-YL)PHENYL)IMIDAZO[1,2-a]PYRAZIN-8-AMINE | Kronos Bio, Inc. | 2021-03-04 | — | — | US | disclosed |
| US-10828299-B2 | Crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine | Kronos Bio, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-10342794-B2 | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20180325896-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2018-11-15 | — | — | US | disclosed |
| US-20180280387-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2018-10-04 | — | — | US | disclosed |
| US-9968601-B2 | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20160375019-A1 | TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE WITH SYK INHIBITORS | Kronos Bio, Inc. | 2016-12-29 | — | — | US | disclosed |
| US-9504684-B2 | Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160310490-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-10-27 | — | — | US | disclosed |
| US-20160058758-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11517570-B2 | Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine | SYK, LCK, LYN | PIK3CA 279/4885PIK3R1 782/4885SYK 1/4885 |
| US-20180280387-A1 | SYK INHIBITORS | SYK, BTK, LYN | PIK3CA 189/4885PIK3R1 99/4885SYK 1/4885 |
| US-20230158023-A1 | CRYSTALLINE SUCCINATE SALT OF 6-(6-AMINOPYRAZIN-2-YL)-N-(4-(4-(OXETAN-3-YL)PIPERAZIN-1-YL)PHENYL)IMIDAZO[1,2-a]PYRAZIN-8-AMINE | SYK, LCK, LYN | PIK3CA 279/4885PIK3R1 782/4885SYK 1/4885 |
| US-20180325896-A1 | SYK INHIBITORS | SYK, BTK, LYN | PIK3CA 165/4885PIK3R1 134/4885SYK 1/4885 |
| US-20160375019-A1 | TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE WITH SYK INHIBITORS | SYK, BTK, ZAP70 | PIK3CA 685/4885PIK3R1 691/4885SYK 1/4885 |
| US-10828299-B2 | Crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine | SYK, LYN, BTK | PIK3CA 218/4885PIK3R1 737/4885SYK 1/4885 |
| US-10342794-B2 | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors | SYK, BTK, LYN | PIK3CA 158/4885PIK3R1 120/4885SYK 1/4885 |
| US-20160310490-A1 | SYK INHIBITORS | SYK, BTK, LYN | PIK3CA 165/4885PIK3R1 134/4885SYK 1/4885 |
| US-20210060011-A1 | CRYSTALLINE MONOMESYLATE SALT OF 6-(6-AMINOPYRAZIN-2-YL)-N-(4-(4-(OXETAN-3-YL)PIPERAZIN-1-YL)PHENYL)IMIDAZO[1,2-a]PYRAZIN-8-AMINE | SYK, LYN, BTK | PIK3CA 218/4885PIK3R1 737/4885SYK 1/4885 |
| US-20160058758-A1 | SYK INHIBITORS | SYK, BTK, LYN | PIK3CA 189/4885PIK3R1 99/4885SYK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.